678161-28-9Relevant academic research and scientific papers
METHODS FOR INHIBITING CASEIN KINASES
-
Paragraph 00265; 00266; 00269; 00270, (2021/10/02)
The present disclosure provides methods for inhibiting CK1 delta or CK1 epsilon activity, comprising administering an effective amount of the compound of Formula (I) to (IV), or a pharmaceutically acceptable salt thereof.
COMPOUNDS AS CASEIN KINASE INHIBITORS
-
, (2021/10/02)
Provided are novel casein kinase inhibitors, or pharmaceutically acceptable salts thereof. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also provided.
Inhibitors of unactivated p38 MAP kinase
Bullington, James,Argentieri, Dennis,Averill, Kristin,Carter, Demetrius,Cavender, Druie,Fahmy, Bohumila,Fan, Xiaodong,Hall, Daniel,Heintzelman, Geoffrey,Jackson, Paul,Leung, Wai-Ping,Li, Xun,Ling, Ping,Olini, Gilbert,Razler, Thomas,Reuman, Michael,Rupert, Kenneth,Russell, Ronald,Siekierka, John,Wadsworth, Scott,Wolff, Russell,Xiang, Bangping,Zhang, Yue-Mei
, p. 6102 - 6106 (2007/10/03)
Inhibition of the p38 map kinase pathway has been shown to be beneficial in the treatment of inflammatory diseases. The first class of potent p38 kinase inhibitors was the pyridinylimidazole compounds from SKB. Since then several pyridinylimidazole-based
3,4-DISUBSTITUTED PYRROLES AND THEIR FOR USE IN TREATING INFLAMMATORY DISEASES
-
Page 67-68, (2010/02/06)
This invention provides novel substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by reducing TNF-α production and/or p38 activity in appropriate cells. This
